---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-071383"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2026-06-08T20:10:52+00:00"
generated_at: "2026-06-08T20:19:19.857306+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics presents preclinical data for CNTY-813; glucose control >8 months, IND on track for Q4 2026

## Summary
- CNTY-813 maintained glucose control for >8 months in diabetic mouse models without immunosuppression.
- No tumorigenesis observed in >140 mice with >1 billion cells infused over 3 months follow-up.
- Allo-Evasion 5.0 edits provided protection from NK cells, antibody-mediated phagocytosis, and maintained insulin secretion in humanized mouse model.
- Phase 1 manufacturing process established; consistent product quality across 11 samples from GMP Master Cell Bank.
- IND submission on track for Q4 2026; initial clinical data expected in 2H 2027.

## SEC filing metadata
- accession: 0001104659-26-071383
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2026-06-08T20:10:52+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465926071383/0001104659-26-071383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465926071383/tm2617028d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-071383
- JSON: https://secwatch.observer/filing/0001104659-26-071383.json
- Plain text: https://secwatch.observer/filing/0001104659-26-071383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.